Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof of concept study evaluating the potential benefit of Liquid Alpha-1 Antitrypsin (AAT) on liver preservation prior to transplantation.

Next Previous
Trial Profile

A proof of concept study evaluating the potential benefit of Liquid Alpha-1 Antitrypsin (AAT) on liver preservation prior to transplantation.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Graft-versus-host disease; Liver transplant rejection
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 05 Sep 2018 Results from the first cohort will be submitted for publication later this year, according to a Kamada media release.
  • 05 Sep 2018 According to a Kamada media release, positive results were obtained from first cohort and the second cohort of the study will be initiated shortly and will assess the effect of AAT with different dosing. Company plans further extension of the study to other solid organs transplantations, if this trial results are positive.
  • 23 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top